BioMarin is pumping the brakes on yet another indication for its CNP analogue, Voxzogo. | The rare disease biotech announced ...
In a push to free itself up for more R&D, Sanofi is acquiring a stake in German drugmaker, Cheplapharm. | In a deal that ...
The FDA has approved the industry’s very first generic radioligand therapy, known as a radioligand equivalent. | The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium ...
The agreement makes AbbVie, which reported $3.2 billion in neuroscience sales in the second quarter, the official pharmaceutical sponsor of the PGA Tour, a professional golf organization. This month’s ...
“In healthcare communications, memorability is what helps turn awareness into action,” Pooja Bhavsar, SVP, strategic planner at The Bloc, said in a statement. “Make the Call was designed to be ...
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk. | GSK is ...
In what signifies the end of a challenging regulatory journey, Scholar Rock secured an FDA approval for its spinal muscular ...
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...
A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...
The fact that Gilead Sciences’ Trodelvy failed as a first-line treatm | Newly revealed global phase 3 data from Merck and ...
Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...
The ink was barely dry on the FDA approval letter for AstraZeneca’s Etcamah before the oral SERD suffered a key clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results